Aflibercept is a recently approved anti-VEGF offering a new therapy for treatment of neovascular AMD. It is a fusion protein of VEGF receptors 1 and 2. It has higher affinity to VEGF compared with ranibizumab or bevacizumab which indicates longer duration of action for aflibercept. In experimental and clinical trials, the efficacy of aflibercept in treatment of AMD has been shown to be comparable to that of ranibizumab and bevacizumab. In studies comparing aflibercept with bevacizumab or ranibizumab, aflibercept had fewer negative effects on retinal cell lines such as change in cell morphology, apoptosis or permanent decrease in cell viability, cell density or proliferation. Aflibercept has greater binding affinity for VEGF than ranibizumab and bevacizumab and requires less-frequent intravitreal injection than ranibizumab and bevacizumab. The vitreous half-life of aflibercept is shorter than bevacizumab, but longer than ranibizumab. In retina pigment epithelium and retina cultures prepared from pigs' eyes, aflibercept completely inhibited VEGF for six hours at a minimal concentration, and displayed a prolonged VEGF inhibition compared to bevacizumab and ranibizumab. However, this advantage of aflibercept raises concerns about possible side effects of long-term usage.